Imo the CMO appointment is another box ticked on the due diligence list, along with the reduction in number of shareholders with unmarketable parcels. Look at the Dimerix website, the structure, the pipeline, the intellectual property held, the cash balance.... Everything is being lined up nicely.
Ann: CMO Appointment and Clinical Trials Update, page-8
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |